NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

OmniAb, Inc. (OABI) Stock Analysis

OmniAb, Inc. (OABI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OABI

$4.33

−$0.42 (−8.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OABI with… →

OABI Key Statistics

As of Sep 4, 2026
Trading
Open
$4.78
Previous Close
$4.75
Day's Range
4.28–4.78
52-Week Range
1.30–5.43
Volume
1.70M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$629.54M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.37
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.33
Financials (FY)
Revenue (FY)
$18.67M−29.27%
Net Income (FY)
−$64.78M
Profit marginThe share of revenue left as profit after all costs and taxes.
−115.12%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
145.39M
1-Year Return
+170.62%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OABI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+134.05%
2025−47.74%
2024−42.63%
2023+71.39%
2022−64.00%
2021 (partial year)+2.46%

As of September 4, 2026.

OABI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$18.67M−$64.78M−347.0%
2024$26.39M−$62.03M−235.1%
2023$34.16M−$50.62M−148.2%
2022$59.08M−$22.33M−37.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$18.67M$18.36M−$68.97M−$64.78M−347.0%
2024$26.39M$26.39M−$74.50M−$62.03M−235.1%
2023$34.16M—−$69.42M−$50.62M−148.2%
2022$59.08M—−$26.65M−$22.33M−37.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OABI Valuation vs Biotechnology Median

Median of 656 stocks
MetricOABIBiotechnology medianvs median
P/S ratio16.3715.267% above
Profit margin−115.12%0.00%115.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

OmniAb, Inc. (OABI) is capitalised at $629.54M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 89.

The 52-week range on file runs from $1.30 to $5.43. The most recent close on file for OABI is $4.33, dated September 4, 2026. That is −$0.42 (−8.84%) against the previous close. The latest close sits 233.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $18.67M. Against the prior fiscal year total of $26.39M, that is a change of −29.27%. The same year closed with a net loss of $64.78M. The reported profit margin is −115.12%. That is 115.1 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.33.

Across the 4 fiscal years on file, revenue moves from $59.08M in 2022 to $18.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 16.37. On price-to-sales that is 7.25% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.42. Annualized volatility over the trailing 4 years is 72.03%. Over the trailing twelve months the price has returned +170.62%. Across 3 years the annualized return works out at −9.44%.

Growth & Income

No dividend is on file for OABI.

2026 is still running; the price is +134.05% year to date. Across the complete calendar years on file, 2023 returned +71.39% and 2022 returned −64.00%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

OmniAb, Inc. (OABI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OmniAb, Inc. OABI $629.54M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. OmniAb, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About OmniAb, Inc.

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Visit website →